NBIX — Neurocrine Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $10.56bn
- $9.48bn
- $2.36bn
- 93
- 37
- 29
- 53
Annual cashflow statement for Neurocrine Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 407 | 89.6 | 155 | 250 | 341 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 161 | 135 | 218 | 147 | 369 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -37.9 | 16.7 | -67.4 | 28.2 | -19.2 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 229 | 257 | 339 | 390 | 595 |
| Capital Expenditures | -10.9 | -23.4 | -16.5 | -28.3 | -38.2 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 15 | -107 | -161 | -439 | -88.6 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 4.1 | -130 | -177 | -467 | -127 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -158 | 27.4 | -234 | 65.3 | -487 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 74.8 | 154 | -73.3 | -11.6 | -18.1 |